Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous nivolumab in previously treated advanced or metastatic clear cell renal cell carcinoma
2023-503280-42-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of nivolumab in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Time-averaged serum concentration over 28 days and Trough serum concentration at steady state. Started Jul 2024; status: completed.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2023-503280-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503280-42-00.